Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.

NCT03205033 is registered in ClinicalTrials.gov with Hospital de Clinicas de Porto Alegre as lead sponsor.

NCT NCT03205033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03205033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.
Lead sponsor
Hospital de Clinicas de Porto Alegre
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2016
Completion date
January 31, 2017
Enrollment
36 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

depression, genotoxicity, pain, sleep disorders, circadian rhythm